# Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

> **NCT00538876** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT00538876
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538876, "Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00538876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*